{"id":798350,"date":"2025-01-07T07:35:38","date_gmt":"2025-01-07T12:35:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/"},"modified":"2025-01-07T07:35:38","modified_gmt":"2025-01-07T12:35:38","slug":"inflarx-announces-participation-in-january-events-in-san-francisco","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/","title":{"rendered":"InflaRx Announces Participation in January Events in San Francisco"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">JENA, Germany, Jan.  07, 2025  (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43<sup>rd<\/sup> Annual J.P. Morgan Healthcare Conference.<\/p>\n<p align=\"justify\">\n        <strong>LifeSci Partners Corporate Access Event<br \/><\/strong>1-on-1 meetings on January 14 and 15, 2025<\/p>\n<p align=\"justify\">\n        <strong>Biotech Showcase 2025<br \/><\/strong>Workshop on January 15, 2025, 8:00 \u2013 9:00 AM PT<\/p>\n<p align=\"justify\">\n        <em>The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World: A Q&amp;A with Government, NGO and Industry Participants <\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>About InflaRx<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx\u2019s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NDajvoCGT8mjY6vkb93DOiOlNr7QpuxyRqogN2QxgdBsmmeOnOKraZV4kkrEgDRyo-YTPkelBUc5ZbavAWoM3A==\" rel=\"nofollow\" target=\"_blank\">www.inflarx.com<\/a>.<\/p>\n<p align=\"justify\">InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Contacts:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>InflaRx N.V.<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>MC Services AG<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Jan Medina, CFA<br \/>Vice President, Head of Investor Relations<br \/>Email: <a href=\"mailto:IR@inflarx.de\" rel=\"nofollow\" target=\"_blank\">IR@inflarx.de<\/a><\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Katja Arnold, Laurie Doyle, Dr. Regina Lutz<br \/>Email: <a href=\"mailto:inflarx@mc-services.eu\" rel=\"nofollow\" target=\"_blank\">inflarx@mc-services.eu<\/a><br \/>Europe: +49 89-210 2280<br \/>U.S.: +1-339-832-0752<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>FORWARD-LOOKING STATEMENTS<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cbelieve,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue,\u201d among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, \u201cRisk factors\u201d and \u201cCautionary statement regarding forward looking statements\u201d, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2ZlZDhhNDAtYmVmOC00Nzk2LThjOTEtNjY1MTAxMzZiZjM0LTEyMDU3OTQ=\/tiny\/InflaRx-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference. LifeSci Partners Corporate Access Event1-on-1 meetings on January 14 and 15, 2025 Biotech Showcase 2025Workshop on January 15, 2025, 8:00 \u2013 9:00 AM PT The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World: A Q&amp;A with Government, NGO and Industry Participants About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InflaRx Announces Participation in January Events in San Francisco&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798350","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InflaRx Announces Participation in January Events in San Francisco - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InflaRx Announces Participation in January Events in San Francisco - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference. LifeSci Partners Corporate Access Event1-on-1 meetings on January 14 and 15, 2025 Biotech Showcase 2025Workshop on January 15, 2025, 8:00 \u2013 9:00 AM PT The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World: A Q&amp;A with Government, NGO and Industry Participants About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a &hellip; Continue reading &quot;InflaRx Announces Participation in January Events in San Francisco&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T12:35:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InflaRx Announces Participation in January Events in San Francisco\",\"datePublished\":\"2025-01-07T12:35:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/\",\"name\":\"InflaRx Announces Participation in January Events in San Francisco - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=\",\"datePublished\":\"2025-01-07T12:35:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-january-events-in-san-francisco\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InflaRx Announces Participation in January Events in San Francisco\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InflaRx Announces Participation in January Events in San Francisco - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/","og_locale":"en_US","og_type":"article","og_title":"InflaRx Announces Participation in January Events in San Francisco - Market Newsdesk","og_description":"JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference. LifeSci Partners Corporate Access Event1-on-1 meetings on January 14 and 15, 2025 Biotech Showcase 2025Workshop on January 15, 2025, 8:00 \u2013 9:00 AM PT The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World: A Q&amp;A with Government, NGO and Industry Participants About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a &hellip; Continue reading \"InflaRx Announces Participation in January Events in San Francisco\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T12:35:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InflaRx Announces Participation in January Events in San Francisco","datePublished":"2025-01-07T12:35:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/"},"wordCount":493,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/","name":"InflaRx Announces Participation in January Events in San Francisco - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=","datePublished":"2025-01-07T12:35:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzIxMSM2NjgwNzM5IzIxOTQyNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-january-events-in-san-francisco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InflaRx Announces Participation in January Events in San Francisco"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798350"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798350\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}